If you have been reading about reference standard and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
There is some difficulty over the correct name of the capital. Early despatches contain reference to both Port Stanley and Stanley. Port Stanley was accepted by the Naming Commission set up in 1943 to consider the names then being included on the War Office maps. Local opinion differs on the matter, but there is no doubt that Stanley is now common usage and has been for some considerable time. The capital is defined as Stanley in the Interpretation and General Law Ordinance. In the circumstances I would advise that the correct name for the capital is Stanley.
Mass media, lawmakers, and Donald Trump raised concerns about Biden's age, including his cognitive state, during and after the 2020 United States presidential election. According to a February 2024 poll, Biden's age and health were major or moderate concerns for 86% of voters generally, up from 76% in 2020. According to another February 2024 poll, most of those who voted for Biden in 2020 believed he was too old to be an effective president; The New York Times noted that these concerns "cut across generations, gender, race and education". Concerns about Biden's age and health increased after a poor performance by Biden during a debate against Trump in June 2024. That performance led a number of commentators and Democratic lawmakers to call for Biden to drop out of the 2024 presidential race. In July 2024, Biden ultimately withdrew from the race while stating that he would continue serving as president until the conclusion of his term.
==== Minoxidil ==== Minoxidil, applied topically, is widely used for the treatment of hair loss. It may be effective in helping promote hair growth in both men and women with androgenic alopecia. About 40% of men experience hair regrowth after 3–6 months. It is the only topical product that is FDA approved in America for androgenic hair loss. However, increased hair loss has been reported.
== Treatment == Treatment for neurofibrosarcoma is similar to that of other cancers. Surgery is an option; the removal of the tumor along with surrounding tissue may be vital for the patient's survival. For discrete, localized tumors, surgery is often followed by radiation therapy of the excised area to reduce the chance of recurrence. For patients who have neurofibrosarcomas in an extremity, if the tumor is vascularized (has its own blood supply) and has many nerves going through it and/or around it, amputation of the extremity may be necessary. Some surgeons argue that amputation should be the procedure of choice when possible, due to the increased chance of a better quality of life. Otherwise, surgeons may opt for a limb-saving treatment, by removing less of the surrounding tissue or part of the bone, which is replaced by a metal rod or grafts. Radiation will also be used in conjunction with surgery, especially if the limb was not amputated. Radiation is rarely used as a sole treatment. In some instances, the oncologist may choose chemotherapy drugs when treating a patient with neurofibrosarcoma, usually in conjunction with surgery. Patients taking chemotherapy must be prepared for the side effects that come with any other chemotherapy treatment, such as; hair loss, lethargy, weakness, etc.
Sources: en.wikipedia.org
=== Brand names === Free alcohol gonadorelin has been sold under the brand names Cryptocur, Cystoréline, Fertagyl, GnRH Serono, Gonadorelin, HRF, Kryptocur, LH-RH, Luforan, Pulstim, Relefact, Relisorm L, Stimu-LH, and Wyeth-Ayest HRF. Gonadorelin diacetate has been sold under the brand names Kryptocur, LHRH Ferring, Lutamin, Lutrelef, Lutrepulse, Relisorm L, and Relisorm. GnRH hydrochloride has been sold under the brand names Factrel, HRF, and Luforan. Additional brand names of gonadorelin and its salts include Acegon, Conceptyl, Cystorelin, Enagon, Equity Oestrus Control, Fertagyl Cattle, Fertiral, Gonabreed, Gonadorelin Interpharm, Gonasyn, Gonavet, Hypocrine, Improvest, LH RH Tanabe, LHRH Ferring, LH-RH Ferring, LH-RH Tanabe, Oestracton, OvaCyst, Ovsynch, OVsynch, Ovurelin, Ovarelin, and Relefact LH-RH. The majority of these brand names are for veterinary use.
The epidermis, "epi" coming from the Greek language meaning "over" or "upon", is the outermost layer of the skin. It forms the waterproof, protective wrap over the body's surface, which also serves as a barrier to infection and is made up of stratified squamous epithelium with an underlying basal lamina.
=== Genetics and heritability === Compared to other major psychiatric conditions, the exploration of genetic underpinnings in BPD remains novel. Estimates suggest the heritability of BPD ranges from 37% to 69%, indicating that human genetic variations account for a substantial portion of the risk for BPD within the population. Twin studies, which often form the basis of these estimates, may overestimate the perceived influence of genetics due to the shared environment of twins, potentially skewing results. Certain studies propose that personality disorders are significantly shaped by genetics, more so than many Axis I disorders, such as depression and eating disorders, and even surpassing the genetic impact on broad personality traits. A twin study found that BPD ranks as the third most heritable among ten surveyed personality disorders. Research involving twin and sibling studies has shown a genetic component to traits associated with BPD, such as impulsive aggression; with the genetic contribution to behavior from serotonin-related genes appearing to be modest. A study conducted by Trull et al. in the Netherlands, which included 711 sibling pairs and 561 parents, aimed to identify genetic markers associated with BPD. This research identified a linkage to genetic markers on chromosome 9 as relevant to BPD characteristics, indicating a significant genetic contribution to the variability observed in BPD features.
Sources: en.wikipedia.org
== Chemistry == MCD peptide is a cationic 22-amino acid residue peptide with two disulfide bridges. Although the MCD peptide sequence shows similarity with apamin, they have different toxic properties. MCD peptide belongs to a large family composed of numerous derivatives detecting specific targets and displaying different toxic effects.
Abrasion Acrocyanosis Actinic prurigo (familial polymorphous light eruption of American Indians, hereditary polymorphous light eruption of American Indians, Hutchinson's summer prurigo, hydroa aestivale) Aerosol burn Benign summer light eruption Beryllium granuloma Black heel and palm (black heel, calcaneal petechiae, chromidrose plantaire, post-traumatic punctate intraepidermal hemorrhage, tache noir) Callus (callosity, clavus, corn, heloma, heloma durum, heloma molle, intractable plantar keratosis, tyloma) Carbon stain Chilblains (pernio, perniosis) Chronic actinic dermatitis (actinic reticuloid, chronic photosensitivity dermatitis, persistent light reactivity, photosensitive eczema) Colloid milium Coma blister Delayed blister Dermatosis neglecta Edema blister (edema bulla, hydrostatic bulla, stasis blister) Electrical burn Equestrian perniosis Erythema ab igne (fire stains, toasted skin syndrome) Erythrocyanosis crurum Favre–Racouchot syndrome (Favre–Racouchot disease, nodular cutaneous elastosis with cysts and comedones) Foreign body reaction Fracture blister Friction blister Frostbite Garrod's pad (violinist's pad) Harpist's finger Heel stick wound Heat edema Hot tar burn Hunan hand syndrome (chili burn) Hydroa vacciniforme (Bazin's hydroa vacciniforme) Jogger's nipple Juvenile spring eruption Kairo cancer Kang cancer Kangri ulcer Lightning burn Loop mark Magnetic resonance imaging burn (MRI burn) Mercury granuloma Miliaria crystallina (miliaria crystalline, sudamina) Miliaria profunda (mammillaria) Miliaria pustulosa Miliaria rubra (heat rash, prickly heat) Narcotic dermopathy Occlusion miliaria Painful fat herniation (painful piezogenic pedal papules, piezogenic papules) Peat fire cancer Photoaging (dermatoheliosis) Photosensitivity with HIV infection Phototoxic tar dermatitis Photosenitization Phytophotodermatitis (Berloque dermatitis) Pinch mark Polymorphous light eruption (polymorphic light eruption) Postmiliarial hypohidrosis Postoperative hematoma Pressure ulcer (decubitus ulcer) Pseudoacanthosis nigricans Pseudoverrucous papules and nodules Pulling boat hands PUVA-induced acrobullous dermatosis Runner's rump Sclerosing lymphangiitis Silica granuloma Silicone granuloma Skin pop scar Skin track Slap mark Solar erythema Soot tattoo Subcutaneous emphysema Sucking blister Sunburn Hell's itch Surfer's knots Talon noir Tattoo Tennis toe Thermal burn Traumatic asphyxia Trench foot Tropical anhidrotic asthenia Tropical immersion foot (paddy foot, paddy-field foot) Turf toe Uranium dermatosis UV-sensitive syndrome Vibration white finger (dead finger, hand–arm vibration syndrome) Warm water immersion foot Weathering nodule of ear Wrestler's ear (cauliflower ear, traumatic auricular hematoma) Zirconium granuloma
==== Elimination ==== MDMA and metabolites are primarily excreted as conjugates, such as sulfates and glucuronides. MDMA is a chiral compound and has been almost exclusively administered as a racemate. However, the two enantiomers have been shown to exhibit different kinetics. The disposition of MDMA may also be stereoselective, with the S-enantiomer having a shorter elimination half-life and greater excretion than the R-enantiomer. Evidence suggests that the area under the blood plasma concentration versus time curve (AUC) was two to four times higher for the (R)-enantiomer than the (S)-enantiomer after a 40 mg oral dose in human volunteers. Likewise, the plasma half-life of (R)-MDMA was significantly longer than that of the (S)-enantiomer (5.8 ± 2.2 hours vs 3.6 ± 0.9 hours). However, because MDMA excretion and metabolism have nonlinear kinetics, the half-lives would be higher at more typical doses (100 mg is sometimes considered a typical dose).
=== YxxCxxxF motif and GTS loop === The YxxCxxxF motif and GTS loop are two amino acid sites that are located in Domain 1 of eRF1. The YxxCxxxF motif is found in the amino acid residues 121-131, whereas the GTS loop is found in amnio acid residues 31-33. The YxxCxxxF is composed of three invariant amino acid residues: Tyrosine (Y), Cysteine (C), and Phenylalanine (F). These sites are structurally separated in the folded eRF1 protein, however their main functions are very similar. They are responsible for purine recognition in position 2 and 3 of the stop codon.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.